CMV Vaccine Study for Liver Transplant Candidates
Part of Digestive system, Immune system & allergy, Infections clinical trials.
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have never had a CMV infection (tested negative for CMV antibodies).
- You are not infected with HIV.
- You are planning to receive your first liver transplant from a living or deceased donor, expected within 1 to 12 months.
- If you are of childbearing potential, you must agree to use contraception for at least 1 month after the last vaccine dose.
- Your platelet count must be at least 20,000 cells/mm³ within the last 3 months.
- You have not received a CMV vaccine before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a higher dose of an experimental vaccine (VIR-1388) that may help prevent infection with cytomegalovirus (CMV), a common virus that can be harmful to people with weakened immune systems and to unborn babies. The vaccine is given to healthy adults who already have CMV to see if it is safe and produces a good immune response.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This trial tests whether using a blood test that measures your immune system's ability to fight CMV (a common virus) can guide when to stop anti-CMV drugs after a lung transplant, aiming to prevent the virus from causing disease.
This study tests a vaccine strategy for people who are being evaluated and waiting for a liver transplant. The goal is to see how well the immune system responds and how the results are interpreted before transplant.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.